New drug cocktail aims to stall advanced prostate cancer in Early-Stage patients
NCT ID NCT03821792
First seen Nov 01, 2025 · Last updated May 30, 2026 · Updated 37 times
Summary
This study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men whose prostate cancer has spread but who have not yet received hormone therapy. The goal is to see how long patients can stay on treatment and to measure cancer progression and side effects. Participants must have high-risk features like a high Gleason score or multiple bone lesions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.